Millington-Ward S - Search Results

1

Toward an elucidation of the molecular genetics of inherited retinal degenerations.

Farrar GJ, Carrigan M, Dockery A, Millington-Ward S, Palfi A, Chadderton N, Humphries M, Kiang AS, Kenna PF, Humphries P. Farrar GJ, et al. Hum Mol Genet. 2017 Aug 1;26(R1):R2-R11. doi: 10.1093/hmg/ddx185. Hum Mol Genet. 2017. PMID: 28510639 Free PMC article. Review.

2

Clinical and molecular genetic characterisation of a family segregating autosomal dominant retinitis pigmentosa and sensorineural deafness.

Kenna P, Mansergh F, Millington-Ward S, Erven A, Kumar-Singh R, Brennan R, Farrar GJ, Humphries P. Kenna P, et al. Br J Ophthalmol. 1997 Mar;81(3):207-13. doi: 10.1136/bjo.81.3.207. Br J Ophthalmol. 1997. PMID: 9135384 Free PMC article.

3

Strategems in vitro for gene therapies directed to dominant mutations.

Millington-Ward S, O'Neill B, Tuohy G, Al-Jandal N, Kiang AS, Kenna PF, Palfi A, Hayden P, Mansergh F, Kennan A, Humphries P, Farrar GJ. Millington-Ward S, et al. Hum Mol Genet. 1997 Sep;6(9):1415-26. doi: 10.1093/hmg/6.9.1415. Hum Mol Genet. 1997. PMID: 9285777

4

Retinitis pigmentosa and progressive sensorineural hearing loss caused by a C12258A mutation in the mitochondrial MTTS2 gene.

Mansergh FC, Millington-Ward S, Kennan A, Kiang AS, Humphries M, Farrar GJ, Humphries P, Kenna PF. Mansergh FC, et al. Am J Hum Genet. 1999 Apr;64(4):971-85. doi: 10.1086/302344. Am J Hum Genet. 1999. PMID: 10090882 Free PMC article.

5

A mutation-independent therapeutic strategem for osteogenesis imperfecta.

Millington-Ward S, O'Neill B, Kiang AS, Humphries P, Kenna PF, Farrar GJ. Millington-Ward S, et al. Antisense Nucleic Acid Drug Dev. 1999 Dec;9(6):537-42. doi: 10.1089/oli.1.1999.9.537. Antisense Nucleic Acid Drug Dev. 1999. PMID: 10645780

6

Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.

O'Neill B, Millington-Ward S, O'Reilly M, Tuohy G, Kiang AS, Kenna PF, Humphries P, Farrar GJ. O'Neill B, et al. Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2863-9. Invest Ophthalmol Vis Sci. 2000. PMID: 10967039

7

Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta.

Millington-Ward S, Allers C, Tuohy G, Conget P, Allen D, McMahon HP, Kenna PF, Humphries P, Farrar GJ. Millington-Ward S, et al. Hum Mol Genet. 2002 Sep 15;11(19):2201-6. doi: 10.1093/hmg/11.19.2201. Hum Mol Genet. 2002. PMID: 12217948

8

Sensitivity of photoreceptor-derived cell line (661W) to baculoviral p35, Z-VAD.FMK, and Fas-associated death domain.

Tuohy G, Millington-Ward S, Kenna PF, Humphries P, Farrar GJ. Tuohy G, et al. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3583-9. Invest Ophthalmol Vis Sci. 2002. PMID: 12407171

9

RNAi of COL1A1 in mesenchymal progenitor cells.

Millington-Ward S, McMahon HP, Allen D, Tuohy G, Kiang AS, Palfi A, Kenna PF, Humphries P, Farrar GJ. Millington-Ward S, et al. Eur J Hum Genet. 2004 Oct;12(10):864-6. doi: 10.1038/sj.ejhg.5201230. Eur J Hum Genet. 2004. PMID: 15241481

10

Emerging therapeutic approaches for osteogenesis imperfecta.

Millington-Ward S, McMahon HP, Farrar GJ. Millington-Ward S, et al. Trends Mol Med. 2005 Jun;11(6):299-305. doi: 10.1016/j.molmed.2005.04.006. Trends Mol Med. 2005. PMID: 15949772 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters